Managed Entry Agreements And Funding For Expensive Therapies (Pharmaceuticals, Health Economics And Market Access) - 9780367500290

Market entry agreement (MEA) for pharmaceuticals has become extremely popular and geographically widely spread. Emerging countries that have not yet begun introducing MEA are actively engaged in doing so. Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable. The authors provide an historical vision of the development of MEA with experiences, failures and successes that have shaped the evolution and place of MEA in access to pharmaceuticals. They provide an extensive review of MEA typology and propose a new one that is pragmatic and actionable. Additional Features include: Discusses the affordability of future therapy and the possible challenges for health insurance systems Addresses the practical and applied issue of market access and includes the most up to date developments such as the Pelosi bill Describes the potential change of paradigm which will challenge all payers and may question the sustainability of our health care systems Highlights the gradual move from repeated treatment administration to one single administration with potential for a definite cure For all stakeholders involved in market access, or students in the field, this book offer an invaluable source of information.

• | Author: Mondher Toumi|Szymon Jaroslawski
• | Publisher: CRC Press
• | Publication Date: Jun 24, 2022
• | Number of Pages: 159 pages
• | Language: English
• | Binding: Hardcover
• | ISBN-10: 0367500299
• | ISBN-13: 9780367500290